Compare BioNTech SE - ADR (BNTX) vs Invesco S&P 500 Low Volatility ETF (SPLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Invesco S&P 500 Low Volatility ETF — how do they compare? BioNTech SE - ADR trades at $89.89 (market cap $22.86B), while Invesco S&P 500 Low Volatility ETF trades at $75.93. The key difference: Invesco S&P 500 Low Volatility ETF is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | SPLV | |
|---|---|---|
Market Cap | $22.86B | — |
Sector | Health | — |
52-Week High | $119.34 | $77.45 |
52-Week Low | $83.89 | $70.30 |
Enterprise Value | $6.53B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
SPLV trades at $76.41, up 0.75% with a bullish technical signal from moving averages. The ETF provides exposure to 100 S&P 500 stocks with the lowest volatility, maintaining strong defensive characteristics with no calendar-year losses exceeding 5% historically. Recent market volatility has increased investor interest in low-volatility strategies as tech valuations remain stretched.
The outlook remains positive given ongoing market uncertainty and inflation concerns. SPLV's defensive positioning offers portfolio stability, though concentrated sector exposure and quarterly rebalancing present implementation risks. The ETF's $6.93 billion in assets demonstrates institutional confidence in its low-volatility approach.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Invesco S&P 500 Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →
